COVIDAR - Arrhythmias in COVID-19

Summary

BACKGROUND AND RATIONALE: There is very limited literature available on the arrhythmia occurrence in the context of an infection by the SARS-CoV2 virus. On the other hand, treatment strategies against the SARS-CoV2 virus may carry a risk of QTc prolongation and pro-arrhythmia/sudden death which may be amplified by concomitant use of other QTc-prolonging drugs and/or ion disbalances. COVIDAR is an international initiative to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, to identify potential modifiable predisposing factors to reduce their incidence and to inform the best arrhythmia management options in this patient population.

MAIN OBJECTIVE: To describe the incidence and type of arrhythmic events in the context of the SARS-CoV2 infection.

STUDY DESIGN: patient registry (observational). Patients will not undergo any additional investigations. Only data that is generated during routine clinical care will be collected.

STUDY POPULATION: Patients admitted to the hospital highly suspected of or with confirmed COVID-19.

Conditions

• COVID
• Arrhythmia
• Torsades de Pointe Caused by Drug
• Qt Interval, Variation in
• Atrioventricular Block
• Atrial Fibrillation
• Bradyarrhythmia
• Ventricular Arrythmia

Sponsors & Collaborators

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  collaborator OTHER

• Istituto Auxologico Italiano

  collaborator OTHER

• St George's University Hospitals NHS Foundation Trust

  collaborator OTHER

• University Hospital, Antwerp

  collaborator OTHER

• European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARDHEART)

  collaborator UNKNOWN

• European Society of Cardiology

  collaborator NETWORK

• Hospital Clinic of Barcelona

  lead OTHER

Principal Investigators

• Elena Arbelo, MD, PhD, MSc · Hospital Clinic of Barcelona

• Arthur A Wilde, MD, PhD · Amsterdam UMC

• Lia Crotti, MD, PhD · Istituto Auxologico Italiano, IRCCS

• Elijah Behr, MD, PhD · St George's University Hospitals NHS Foundation Trust

• Hein Heidbuchel, MD, PhD · University Hospital, Antwerp

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-06-30

Primary Completion

2020-12-31

Completion

2021-12-31

Countries

• Belgium
• Italy
• Netherlands
• Spain
• United Kingdom

Study Locations